Literature DB >> 18398232

A novel method of PercuSurge distal protection in a five French guiding catheter without an Export aspiration catheter.

Fuminobu Yoshimachi1, Yuji Ikari, Takashi Matsukage, Motomaru Masutani, Yasuhiro Mori, Shigeru Saito, Ken Okumura.   

Abstract

BACKGROUND AND OBJECTIVES: Although the PercuSurge (PS) system is an efficient distal protection device, it has several limitations such as significant occlusion time causing myocardial ischemia and requirement of a large 7 or 8 Fr guiding catheter (GC). To address these problems, we developed a new method of use for the PS system using a deeply-engaged 5 Fr GC as an aspiration catheter instead of the Export aspiration catheter.
METHODS: We studied the initial feasibility and safety of 14 patients treated with a new PS procedure compared to 18 patients treated with the conventional method.
RESULTS: Clinical and demographic characteristics were similar between the two patient groups. Device success rate was also similar. The new method using a 5 Fr GC without the Export aspiration catheter significantly reduced fluoroscopic time, total procedure time, occlusion time and in-hospital costs.
CONCLUSIONS: This method may be an important alternative procedure that compensates for the disadvantages associated with the conventional use of the PS system by taking advantage of the flexibility and versatility of a 5 Fr GC.

Entities:  

Mesh:

Year:  2008        PMID: 18398232

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  2 in total

1.  Successful percutaneous coronary intervention using a 4-in-3 "Slender Mother and Child" PCI technique.

Authors:  Tsuyoshi Honda; Kazuteru Fujimoto; Yuji Miyao
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-09-16       Impact factor: 1.426

2.  Feasibility of virtual 3-Fr percutaneous coronary intervention using standard guiding catheters.

Authors:  Tsuyoshi Honda; Kazuteru Fujimoto; Yuji Miyao
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-11-17       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.